Why is Insmed (INSM) stock up today?

Insmed shares jumped from a previous close of $99.02 to as high as $137.70 intraday on August 6, 2026 — a gain of roughly 34% — after the company reported second-quarter 2026 results showing its drug BRINSUPRI surged 49% sequentially in revenue. The blowout growth was the dominant catalyst: investors and institutions who had been waiting for commercial proof of BRINSUPRI's trajectory moved quickly to buy on confirmation of the acceleration.

Beyond the top-line revenue beat, Insmed raised its BRINSUPRI revenue guidance for the full year and expanded its peak sales outlook — a double signal that management's confidence in the drug's commercial ramp has increased. On the earnings-per-share side, Insmed reported Q2 EPS of -$0.06, dramatically better than the consensus estimate of -$0.68, suggesting costs are being managed more tightly than the market had anticipated even as the revenue ramp continues.

The move put Insmed at the top of a broader biotech rally on the day, according to Investor's Business Daily. Healthcare stocks were broadly advancing pre-market, with the sector ETF IBB among those moving higher ahead of the open. That constructive sector backdrop amplified the stock-specific reaction to Insmed's results.

The broader equity market provided little tailwind — the S&P 500 slipped 0.18% and the Nasdaq 100 fell 0.37% on the day as a rebound in oil prices weighed on sentiment. Insmed's outsized move was therefore stock-specific, driven by the Q2 earnings and guidance revision rather than any index-level lift. As of the close, Insmed's market capitalization stood at approximately $28.73 billion.